<DOC>
	<DOCNO>NCT00885170</DOCNO>
	<brief_summary>The study evaluate efficacy odanacatib Bone Mineral Density ( BMD ) safety odanacatib postmenopausal osteoporosis patient previously treat alendronate</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Efficacy Odanacatib ( MK0822 ) Postmenopausal Women Previously Treated With Bisphosphonate ( 0822-042 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Patient postmenopausal least 5 year Patient take take alendronate Patient agree use medication osteoporosis provide study Patient history evidence hip fracture Patient history cancer within 5 year screen , except certain skin cervical cancer . Patient active parathyroid disease Patient history thyroid disease adequately control medication Patient take antiseizure medication abnormal calcium metabolism Patient receive bisphosphonate alendronate 20 % last 3 year , within 3 month screen</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>